August 13th Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Akers Biosciences, Inc. (AKER)

LOS ANGELES--()--National securities litigation law firm Glancy Prongay & Murray LLP (“GPM”) reminds investors of the August 13, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Akers Biosciences, Inc. (“Akers” or the “Company”) (NASDAQ: AKER) securities between May 15, 2017 through June 5, 2018, inclusive (the “Class Period”). Akers investors have until August 13, 2018 to file a lead plaintiff motion.

If you are a shareholder who suffered a loss, click here to participate.

Investors suffering losses on their Akers investments are encouraged to contact Lesley Portnoy of GPM to discuss their legal rights in this class action at 310-201-9150 or by email to shareholders@glancylaw.com.

On May 21, 2018, Akers disclosed it was unable to file its Form 10-Q with the SEC for the quarter ended March 31, 2018 and that its continuing review of the “characterization of certain revenue recognition items . . . now includes certain transactions in previous quarters.” On this news, shares of Akers fell $0.058 or over 8% to close at $0.599 on May 22, 2018.

Then on May 29, 2018, Akers issued a press release stating that “Raymond F. Akers Jr., Ph.D has resigned as a director of the Company with immediate effect.” On this news, shares of Akers fell $0.198 or over 33% to close at $0.391 on May 29, 2018, thereby injuring investors.

The complaint filed in this class action alleges that, defendants made false and/or misleading statements and/or failed to disclose that: (1) Akers was improperly recognizing revenue for the fiscal year ended December 31, 2017; (2) Akers had downplayed weaknesses in its internal controls over financial reporting and failed to disclose the true extent of those weaknesses; and (3) as a result, defendants’ statements about Akers’ business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased shares of Akers during the Class Period you may move the Court no later than August 13, 2018 to ask the Court to appoint you as lead. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay and Murray LLP, Los Angeles
Lesley Portnoy, 310-201-9150 or 888-773-9224
www.glancylaw.com
shareholders@glancylaw.com

Release Summary

August 13th Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Akers Biosciences, Inc.

$Cashtags

Contacts

Glancy Prongay and Murray LLP, Los Angeles
Lesley Portnoy, 310-201-9150 or 888-773-9224
www.glancylaw.com
shareholders@glancylaw.com